Xcovery LLC
Aiming to improve on top-selling oncology drugs
This article was originally published in Start Up
Executive Summary
These days, almost all cancers are treated with more than a single drug; the combinations typically include some type of chemotherapy and where possible an agent targeted at a particular mechanism known to be driving tumor growth. Clinicians are always striving to maximize the cancer-killing potential of a drug while minimizing the side effects caused by inherently toxic chemicals. The founders of Xcovery LLC are betting that anti-cancer compounds the firm is now developing will prove considerably less toxic than some of the most popular “targeted” oncology drugs prescribed today. If early clinical data bear out, the start-up anticipates that its orally available small molecules will eventually replace more toxic drugs frequently given in combinations, and so win market share from current leaders.